Elysee Netherlands uses medication from the class of new satiety hormones – incretins – administered subcutaneously on a weekly basis. Incretins are hormones that are naturally found in the intestines. While eating, these hormones stimulate the pancreas to release insulin. The incretin hormone, together with the leptide hormone, causes decreased appetite and delayed gastric emptying.
Weight loss is partly dependent on personal lifestyle. On average, participants in the studies below lost about 15.6% of their body weight over a 4-6 month period*.
*See publication: Mehta A et al. | Obes Sci Pract. 2017; 3(1): 3-14.
**See Publication: Wilding J.P.H., Batterham R.L., Calanna S., et al. | 10.1056/NEJMoa2032183
Use of the new satiety hormone reduces appetite and slows gastric emptying. In addition, the brain releases less of the hunger hormone “ghrelin” to the pituitary gland. This makes it more successful to eat less and the client feels satisfied longer. Also, this reduces the urge for “cravings”.
The most common side effects are nausea and diarrhoea. They occur in more than 10% of clients and are transient. Other side effects, such as vomiting, abdominal pain, constipation, and gastritis, occur in 1 to 10% of clients and are also transient. This new class of satiety hormones are reimbursed in patients with type 2 diabetes under certain conditions.
The use of this new class of satiety hormones is advised against in pregnancy and lactation. There are no known significant interactions of this medication with other medications. During the initial consultation, we will check if there are other reasons why it is better not to use satiety hormones. Clients with type 2 diabetes are advised to contact their primary care physician.
The treatment programme lasts a minimum of 6 months during which the clients are intensively supervised in weight loss and medication by the New Life Nurse. This is followed by a post-treatment program during which clients remain at stable weight levels.
The integral treatment programme consists of an intake interview with a doctor, blood tests, intensive support (home visits) by the New Life Nurse of Elysee, the patient journey app, weight measurements, exercise and nutrition advice. The personal family physician may be contacted for treatment recommendations.
The total cost for the treatment process will be shared with you in advance and is based on the type of process a client will be going through. The cost of consultations, medication, blood pressure measurements and body analysis is all-inclusive. Elysee may bill your health insurance company for the cost of the blood test.
The weight reduction results per client depend on client motivation, medication dosage, the duration of the treatment programme, and adherence to exercise and nutrition recommendations. The average results for weight loss +/- 15.6% are a manufacturer’s statement.
The maintenance dose of saturation hormone is 2.4mg once a week. This is achieved by periodically increasing the starting dose of 0.25mg. This dose will be adjusted after 3 to 4 weeks by the New Life Nurse based on body weight and gastrointestinal side effects. The standard construction is :
- Week 1-4 1 per week 0.25 mg
- Week 5-8 1 per week 0.5 mg
- Week 9-12 1 per week 1.0 mg
- Week 13-16 1 per week 1.7 mg
- Maintenance dose 1 per week 2.4 mg
There are many lifestyle programmes for weight loss. Elysee’s integrative treatment programme is based on a new EMA and FDA approved weight loss drug. Clients quickly experience positive results without drastically changing their lifestyles. The intensive and personal guidance provided by the New Life Nurses gives a boost to clients’ motivation.
The Elysee treatment programme is for individuals with a BMI > 27 who are motivated to participate for at least 6 months. Blood tests and intake by the Elysee physician are standard components of the treatment programme. Medical supervision is aimed at minimizing the possible side effects of the drug and at client self-efficacy.